TY - JOUR
T1 - Antithrombotic therapies. anticoagulation and thrombolysis.
AU - Goel, Ruchika
AU - Vedantham, Suresh
AU - Goldenberg, Neil A.
PY - 2013/12
Y1 - 2013/12
N2 - Pediatric deep vein thrombosis is an increasingly recognized phenomenon, especially with advances in treatment and supportive care of critically ill children and with better diagnostic capabilities. High-quality evidence and uniform management guidelines for antithrombotic treatment, particularly thrombolytic therapy, remain limited. Optimal dosing, intensity and duration strategies for anticoagulation as well as thrombolytic regimens that maximize efficacy and safety need to be determined through well-designed clinical trials using use of a risk-stratified approach.
AB - Pediatric deep vein thrombosis is an increasingly recognized phenomenon, especially with advances in treatment and supportive care of critically ill children and with better diagnostic capabilities. High-quality evidence and uniform management guidelines for antithrombotic treatment, particularly thrombolytic therapy, remain limited. Optimal dosing, intensity and duration strategies for anticoagulation as well as thrombolytic regimens that maximize efficacy and safety need to be determined through well-designed clinical trials using use of a risk-stratified approach.
KW - Anticoagulant
KW - Deep vein thrombosis
KW - Pediatrics
KW - Thrombolysis
KW - Venous thromboembolism
UR - http://www.scopus.com/inward/record.url?scp=84887549381&partnerID=8YFLogxK
U2 - 10.1016/j.pcl.2013.09.005
DO - 10.1016/j.pcl.2013.09.005
M3 - Review article
C2 - 24237982
AN - SCOPUS:84887549381
SN - 0031-3955
VL - 60
SP - 1463
EP - 1474
JO - Pediatric Clinics of North America
JF - Pediatric Clinics of North America
IS - 6
ER -